0001564590-21-024988 | 10-Q | XBRL Viewer

Earnings (Loss) Per Share (Tables)

3 Months Ended

Mar. 31, 2021

Computations of Basic and Diluted Earnings (Loss) Per Share

The computations of basic and diluted earnings (loss) per share are as follows:

	Three Months
	Ended March 31,
	2021		2020

Net income (loss)	$	3,774	$	(7,328	)
Weighted-average shares of common stock outstanding:
Basic		71,878		61,927
Dilutive effect of stock options, restricted stock, and performance stock units		888		—
Diluted		72,766		61,927
Earnings (loss) per share:
Basic	$	0.05	$	(0.12	)
Diluted	$	0.05	$	(0.12	)

Leases - Schedule of Minimum Lease Payments by Period Expected (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Finance Lease Liabilities, Payments, Due [Abstract]
2021 (excluding the three months ended March 31, 2021)	$ 424
2022	566
2023	336
2024	25
2025	5
Total Minimum Finance Lease Payments	1,356
Less: imputed interest	(72)
Present Value of Finance Lease Liabilities	1,284	$ 1,412
Operating Lease Liabilities, Payments Due [Abstract]
2021 (excluding the three months ended March 31, 2021)	1,236
2022	1,616
2023	901
2024	909
2025	518
Thereafter	323
Total Minimum Operating Lease Payments	5,503
Less: imputed interest	(503)
Present Value of Operating Lease Liabilities	$ 5,000	$ 4,716

Leases - Summary of Components of Lease Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Lease Cost [Abstract]
Operating Lease Cost	$ 420	$ 313
Finance Lease Cost
Amortization of right-of use assets	127	163
Interest on lease liabilities	14	20
Total Finance Lease Cost	$ 141	$ 183

Business Combinations (Tables)

3 Months Ended

Mar. 31, 2021

Business Combinations [Abstract]

Summary of Change in Contingent Consideration

The following table represents the change in contingent consideration:

Balance as of December 31, 2020	$	2,451
Payments made during the period		(406	)
Change in fair value during the period		(806	)
Balance as of March 31, 2021	$	1,239

Business Segment Information - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2021 Segment
Segment Reporting [Abstract]
Number of reportable segments of company	2

Earnings (Loss) Per Share - Additional Information (Detail) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Common Stock Options Unvested Restricted Stock and Unvested Performance Stock Units [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Number of anti-dilutive securities excluded from EPS computation	421	312

Commitments and Contingencies

3 Months Ended

Mar. 31, 2021

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

11.	Commitments and Contingencies

From time to time, we are involved in certain legal actions arising in the ordinary course of business. In management’s opinion, the outcomes of such actions, either individually or in the aggregate, are not expected to have a material adverse effect on our future financial position or results of operations.

Inventories - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Inventory Net [Abstract]
Inventories	$ 40,350	$ 31,863
Pre-launch inventory associated with COVID products	$ 2,722

Leases

3 Months Ended

Mar. 31, 2021

Lessee Disclosure [Abstract]

Leases

We determine whether an arrangement is a lease at inception. We have operating and finance leases for corporate offices, warehouse space and equipment (including vehicles). As of March 31, 2021, we are the lessee in all agreements. Our leases have remaining lease terms of 1 to 7 years, some of which include options to extend the leases based on agreed upon terms, and some of which include options to terminate the leases within 1 year.

As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments.

We have lease agreements that contain both lease and non-lease components (e.g., common-area maintenance). For these agreements, we account for lease components separate from non-lease components.

The components of lease expense are as follows:

	Three Months Ended
	2021		2020
Operating Lease Cost	$	420	$	313
Finance Lease Cost
Amortization of right-of use assets		127		163
Interest on lease liabilities		14		20
Total Finance Lease Cost	$	141	$	183

Supplemental cash flow information related to leases is as follows:

	Three Months Ended
	2021		2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	408	$	316
Operating cash flows from financing leases		14		20
Financing cash flows from financing leases		282		175
Non-cash activity:
Right-of-use assets obtained in exchange for operating lease obligations		629		—
Right-of-use assets obtained in exchange for finance lease obligations		—		—

Supplemental balance sheet information related to leases is as follows:

	March 31, 2021		December 31, 2020
Operating Leases
Right-of-use assets	$	4,871	$	4,461

Current lease liabilities		1,443		1,125
Non-current lease liabilities		3,557		3,591
Total operating lease liabilities	$	5,000	$	4,716


Finance Leases
Right-of-use assets	$	1,184	$	1,312

Current lease liabilities		522		517
Non-current lease liabilities		762		895
Total finance lease liabilities	$	1,284	$	1,412

Weighted Average Remaining Lease Term
Weighted-average remaining lease term—operating leases	3.99
Weighted-average remaining lease term—finance leases	2.43

Weighted Average Discount Rate
Weighted-average discount rate—operating leases	4.12	%
Weighted-average discount rate—finance leases	4.39	%

As of March 31, 2021, minimum lease payments by period are expected to be as follows:


	Finance			Operating
2021 (excluding the three months ended March 31, 2021)	$	424		$	1,236
2022		566			1,616
2023		336			901
2024		25			909
2025		5			518
Thereafter		—			323
Total Minimum Lease Payments		1,356			5,503
Less: imputed interest		(72	)		(503	)
Present Value of Lease Liabilities	$	1,284		$	5,000

The Company - Additional Information (Detail)	3 Months Ended
The Company - Additional Information (Detail)	Mar. 31, 2021 Segment
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Number of Segments of company	2

Leases - Summary of Lease Term and Discount Rate (Detail)	Mar. 31, 2021
Weighted Average Remaining Lease Term
Weighted-average remaining lease term—operating leases	3 years 11 months 26 days
Weighted-average remaining lease term—finance leases	2 years 5 months 4 days
Weighted Average Discount Rate
Weighted-average discount rate—operating leases	4.12%
Weighted-average discount rate—finance leases	4.39%

Earnings (Loss) Per Share

3 Months Ended

Mar. 31, 2021

Earnings Per Share [Abstract]

Earnings (Loss) Per Share

5. Earnings (Loss) Per Share

Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed in a manner similar to basic earnings (loss) per share except that the weighted-average number of shares outstanding is increased to include incremental shares from the assumed vesting or exercise of dilutive securities, such as common stock options, unvested restricted stock or performance stock units, unless the impact is antidilutive. The number of incremental shares is calculated by assuming that outstanding stock options were exercised and unvested restricted shares and performance stock units were vested, and the proceeds from such exercises or vesting were used to acquire shares of common stock at the average market

price during the reporting period. Basic and dilutive computations of net loss per share are the same in periods in which a net loss exists as the dilutive effects of excluded items would be anti-dilutive.

The computations of basic and diluted earnings (loss) per share are as follows:

	Three Months
	Ended March 31,
	2021		2020

Net income (loss)	$	3,774	$	(7,328	)
Weighted-average shares of common stock outstanding:
Basic		71,878		61,927
Dilutive effect of stock options, restricted stock, and performance stock units		888		—
Diluted		72,766		61,927
Earnings (loss) per share:
Basic	$	0.05	$	(0.12	)
Diluted	$	0.05	$	(0.12	)

For the three months ended March 31, 2021, outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 421 shares were excluded from the computation of diluted earnings per share as their inclusion would have been anti-dilutive. For the three months ended March 31, 2020, outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 312 shares were excluded from the computation of diluted loss per share.

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash and cash equivalents	$ 177,676		$ 160,802
Fair value of plan assets	2,396		2,565
Accumulated depreciation of property and equipment	55,251		53,604
Accumulated amortization of intangible assets	28,128		27,107
Intangible Assets, Net	16,945		17,904
Intangible Assets, Accumulated Amortization	812
Intangible Assets, Foreign currency translation losses	147
Amount of goodwill at period end	40,493		40,351
Goodwill, acquired during period	18
Adjustment in goodwill associated with foreign currency translation	124
Net foreign exchange gains (losses)	(576)	$ 693
Accumulated foreign currency adjustments included in other comprehensive loss amounted	7,397		8,749
Unrealized loss on marketable securities	$ 327		348
Minimum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Intangible Assets, Amortization Period (Years)	5 years
Minimum [Member] \| Buildings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	20 years
Minimum [Member] \| Computer Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	2 years
Minimum [Member] \| Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	2 years
Minimum [Member] \| Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	2 years
Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Intangible Assets, Amortization Period (Years)	15 years
Maximum [Member] \| Buildings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	40 years
Maximum [Member] \| Computer Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	10 years
Maximum [Member] \| Machinery and Equipment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	10 years
Maximum [Member] \| Furniture and Fixtures [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Estimated useful lives of assets	10 years
Money Market Fund [Member] \| Level I Instruments [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cash and cash equivalents	$ 72,979		$ 71,489

Inventories - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Inventory Net [Abstract]
Raw materials	$ 15,484	$ 15,425
Work in process	3,857	2,572
Finished goods	21,009	13,866
Inventories	$ 40,350	$ 31,863

Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2021

Summary of Reconciliation of Changes in Stockholders' Equity

Reconciliation of the changes in stockholders' equity for the three months ended March 31, 2021 and 2020
	Common Stock					Additional Paid-in			Accumulated Other Comprehensive			Accumulated
	Shares			Amount		Capital			Loss			Deficit			Total
Balance at December 31, 2020		71,738		$	—	$	505,123		$	(9,097	)	$	(97,455	)	$	398,571
Common stock issued upon exercise of options		11			—		92			—			—			92
Vesting of restricted stock and performance stock units		318			—					—			—			—
Purchase and retirement of common shares		(111	)		—		(1,730	)		—			—			(1,730	)
Stock-based compensation		—			—		1,464			—			—			1,464
Net income		—			—		—			—			3,774			3,774
Currency translation adjustments		—			—		—			1,352			—			1,352
Unrealized gain on marketable securities		—			—		—			21			—			21
Balance at March 31, 2021		71,956		$	—	$	504,949		$	(7,724	)	$	(93,681	)	$	403,544


	Common Stock					Additional Paid-in			Accumulated Other Comprehensive			Accumulated
	Shares			Amount		Capital			Loss			Deficit			Total
Balance at December 31, 2019		61,731		$	—	$	401,814		$	(12,136	)	$	(82,533	)	$	307,145
Common stock issued upon exercise of options		6			—		30			—			—			30
Vesting of restricted stock and performance stock units		486			—		—			—			—			—
Purchase and retirement of common shares		(197	)		—		(1,408	)		—			—			(1,408	)
Stock-based compensation		—			—		1,376			—			—			1,376
Net loss		—			—		—			—			(7,328	)		(7,328	)
Currency translation adjustments		—			—		—			(9,221	)		—			(9,221	)
Unrealized loss on marketable securities		—			—		—			(442	)		—			(442	)
Balance at March 31, 2020		62,026		$	—	$	401,812		$	(21,799	)	$	(89,861	)	$	290,152

Summary of Company's Stock Option Activity

The following table summarizes the stock option activity for the three months ended March 31, 2021:

	Options
Outstanding on January 1, 2021		1,232
Granted		252
Exercised		(11	)
Forfeited		(23	)
Outstanding on March 31, 2021		1,450

Summary of Time-Vested Restricted Stock Award and Restricted Stock Units Activity

The following table summarizes time-vested restricted stock award and restricted stock unit activity for the three months ended March 31, 2021:

	Units
Issued and unvested, January 1, 2021		659
Granted		275
Vested		(206	)
Forfeited		(5	)
Issued and unvested, March 31, 2021		723

Performance Based Restricted Stock Unit [Member]

Summary of Performance Based Restricted Stock Unit Award Activity Under Stock Plan

The following table summarizes the PSU activity for the three months ended March 31, 2021:

	Units
Issued and unvested, January 1, 2021		651
Granted		186
Performance adjustment		37
Vested		(112	)
Forfeited		(49	)
Issued and unvested, March 31, 2021		713

Inventories

3 Months Ended

Mar. 31, 2021

Inventory Disclosure [Abstract]

Inventories

4. Inventories

	March 31, 2021		December 31, 2020
Raw materials	$	15,484	$	15,425
Work in process		3,857		2,572
Finished goods		21,009		13,866
	$	40,350	$	31,863

The inventory balance of $40,350 as of March 31, 2021 includes $2,722 of pre-launch inventory associated with our COVID products for which an application for regulatory approval has been submitted to the FDA but approval has not yet been received as of March 31, 2021. We expect our COVID products will be granted regulatory approval, however, should this not occur, the pre-launch inventory balance would be written-off through our statement of operations.

Inventories (Tables)

3 Months Ended

Mar. 31, 2021

Inventory Disclosure [Abstract]

Schedule of Inventories

	March 31, 2021		December 31, 2020
Raw materials	$	15,484	$	15,425
Work in process		3,857		2,572
Finished goods		21,009		13,866
	$	40,350	$	31,863

Revenues - Summary of Total Net Revenues by Product Line (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Disaggregation Of Revenue [Line Items]
Net revenues	$ 58,582	$ 31,596
Product and Services Revenues [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	56,579	30,886
Product and Services Revenues [Member] \| Infectious Disease Testing [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	11,371	14,664
Product and Services Revenues [Member] \| Risk Assessment Testing [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	1,962	3,000
Product and Services Revenues [Member] \| Genomics [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	11,064	8,393
Product and Services Revenues [Member] \| Microbiome [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	2,088	1,577
Product and Services Revenues [Member] \| COVID-19 [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	27,389	394
Product and Services Revenues [Member] \| Laboratory Services [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	2,497	2,415
Product and Services Revenues [Member] \| Other Product and Service Revenues [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	208	443
Other [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	2,003	710
Other [Member] \| Royalty Income [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	1,261	446
Other [Member] \| Other Non Product Revenues [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	$ 742	$ 264

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current Assets:
Cash and cash equivalents	$ 177,676	$ 160,802
Short-term investments	29,080	48,599
Accounts receivable, net of allowance for doubtful accounts of $4,279 and $3,654	36,391	38,835
Inventories	40,350	31,863
Prepaid expenses	6,030	3,860
Other current assets	2,883	4,934
Total current assets	292,410	288,893
Noncurrent Assets:
Property, plant and equipment, net	64,943	51,860
Operating right-of-use assets, net	4,871	4,461
Finance right-of-use assets, net	1,184	1,312
Intangible assets, net	16,945	17,904
Goodwill	40,493	40,351
Long-term investments	33,706	47,718
Other noncurrent assets	1,944	1,973
Total noncurrent assets	164,086	165,579
TOTAL ASSETS	456,496	454,472
Current Liabilities:
Accounts payable	20,731	17,407
Deferred revenue	4,580	4,811
Accrued expenses and other current liabilities	17,003	22,227
Finance lease liability	522	517
Operating lease liability	1,443	1,125
Acquisition-related contingent consideration obligation	365	402
Total current liabilities	44,644	46,489
Noncurrent Liabilities:
Finance lease liability	762	895
Operating lease liability	3,557	3,591
Acquisition-related contingent consideration obligation	874	2,049
Other noncurrent liabilities	1,997	1,682
Deferred income taxes	1,118	1,195
Total noncurrent liabilities	8,308	9,412
TOTAL LIABILITIES	52,952	55,901
Commitments and contingencies (Note 11)
STOCKHOLDERS' EQUITY
Preferred stock, par value $.000001, 25,000 shares authorized, none issued
Common stock, par value $.000001, 120,000 shares authorized, 71,956 and 71,738 shares issued and outstanding	0	0
Additional paid-in capital	504,949	505,123
Accumulated other comprehensive loss	(7,724)	(9,097)
Accumulated deficit	(93,681)	(97,455)
Total stockholders' equity	403,544	398,571
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 456,496	$ 454,472

Revenues - Summary of Total Net Revenues by Geographic Area (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Disaggregation Of Revenue [Line Items]
Net revenues	$ 58,582	$ 31,596
United States [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	49,100	21,616
Europe [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	4,552	2,805
Other Regions [Member]
Disaggregation Of Revenue [Line Items]
Net revenues	$ 4,930	$ 7,175

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Business Combinations - Summary of Change in Contingent Consideration (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Business Combination Contingent Consideration Arrangements [Abstract]
Beginning Balance	$ 2,451
Payments made during the period	(406)
Change in fair value during the period	(806)	$ 1,110
Ending Balance	$ 1,239

Stockholders' Equity - Summary of Performance Based Restricted Stock Unit Award Activity Under Stock Plan (Detail) - Performance Based Restricted Stock Unit [Member] shares in Thousands	3 Months Ended
	Mar. 31, 2021 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Issued and unvested, Beginning Balance	651
Shares, Granted	186
Performance adjustment	37
Shares, Vested	(112)
Shares, Forfeited	(49)
Shares, Issued and unvested, Ending Balance	713

Business Segment Information - Summary of Operating Segment and Asset Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Segment Reporting Information [Line Items]
Net revenues	$ 58,582	$ 31,596
Operating income (loss)	10,422	(8,046)
Depreciation and amortization	2,489	2,197
Capital expenditures	11,061	2,595
Total assets	456,496		$ 454,472
Diagnostics [Member]
Segment Reporting Information [Line Items]
Net revenues	14,546	17,792
Operating income (loss)	(12,193)	(7,641)
Depreciation and amortization	890	861
Capital expenditures	7,637	818
Total assets	221,858		242,613
Molecular Solutions [Member]
Segment Reporting Information [Line Items]
Net revenues	44,036	13,804
Operating income (loss)	22,615	(405)
Depreciation and amortization	1,599	1,336
Capital expenditures	3,424	$ 1,777
Total assets	$ 234,638		$ 211,859

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2021

Accounting Policies [Abstract]

Summary of Available-for-sale Securities

The following is a summary of our available-for-sale securities as of March 31, 2021 and December 31, 2020:

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
March 31, 2021
Guaranteed investment certificates	$	25,470	$	—	$	—		$	25,470
Corporate bonds		37,643		48		(375	)		37,316
Total available-for-sale securities	$	63,113	$	48	$	(375	)	$	62,786
December 31, 2020
Guaranteed investment certificates	$	25,132	$	—	$	—		$	25,132
Corporate bonds		71,533		135		(483	)		71,185
Total available-for-sale securities	$	96,665	$	135	$	(483	)	$	96,317
At March 31, 2021, maturities of our available-for-sale securities were as follows:
Less than one year	$	29,334	$	48	$	(302	)	$	29,080
Greater than one year	$	33,779	$	—	$	(73	)	$	33,706

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Statement Of Income And Comprehensive Income [Abstract]
NET INCOME (LOSS)	$ 3,774	$ (7,328)
OTHER COMPREHENSIVE INCOME (LOSS)
Currency translation adjustments	1,352	(9,221)
Unrealized gain (loss) on marketable securities	21	(442)
COMPREHENSIVE INCOME (LOSS)	$ 5,147	$ (16,991)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

Leases - Additional Information (Detail)	3 Months Ended
Leases - Additional Information (Detail)	Mar. 31, 2021
Lessee Lease Description [Line Items]
Lessee operating and financing lease existence of option to terminate	true
Lessee operating and financing leases, period of options to terminate	1 year
Lessee, operating and finance lease, existence of option to extend	true
Minimum [Member]
Lessee Lease Description [Line Items]
Operating and financing leases, remaining lease terms	1 year
Maximum [Member]
Lessee Lease Description [Line Items]
Operating and financing leases, remaining lease terms	7 years

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Statement Of Financial Position [Abstract]
Allowance for doubtful accounts	$ 4,279	$ 3,654
Preferred stock, par value	$ 0.000001	$ 0.000001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.000001	$ 0.000001
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	71,956,000	71,738,000
Common stock, shares outstanding	71,956,000	71,738,000

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2021	May 01, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Trading Symbol	OSUR
Entity Registrant Name	ORASURE TECHNOLOGIES, INC
Entity Central Index Key	0001116463
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Title of 12(b) Security	Common Stock, $0.000001 par value per share
Security Exchange Name	NASDAQ
Entity File Number	001-16537
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	36-4370966
Entity Address, Address Line One	220 East First Street
Entity Address, City or Town	Bethlehem
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	18015
City Area Code	610
Local Phone Number	882-1820
Entity Common Stock, Shares Outstanding		71,960,048
Document Quarterly Report	true
Document Transition Report	false

Stockholders' Equity - Summary of Company's Stock Option Activity (Detail) shares in Thousands	3 Months Ended
	Mar. 31, 2021 shares
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward
Options, Outstanding, Beginning Balance	1,232
Options, Granted	252
Options, Exercised	(11)
Options, Forfeited	(23)
Options, Outstanding, Ending Balance	1,450

Accrued Expenses and Other Current Liabilities

3 Months Ended

Mar. 31, 2021

Payables And Accruals [Abstract]

Accrued Expenses and Other Current Liabilities

7.	Accrued Expenses and other current liabilities

	March 31, 2021		December 31, 2020
Payroll and related benefits	$	8,037	$	14,769
Professional fees		1,150		978
Accrued income taxes		2,507		—
Sales tax payable		2,572		2,400
Other		2,737		4,080
	$	17,003	$	22,227

Summary of Significant Accounting Policies - Summary of Available-for-sale Securities (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 63,113	$ 96,665
Gross Unrealized Gains	48	135
Gross Unrealized Losses	(375)	(483)
Fair Value	62,786	96,317
Guaranteed Investment Certificates [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	25,470	25,132
Gross Unrealized Gains	0	0
Fair Value	25,470	25,132
Corporate Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	37,643	71,533
Gross Unrealized Gains	48	135
Gross Unrealized Losses	(375)	(483)
Fair Value	37,316	$ 71,185
Less Than One Year [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	29,334
Gross Unrealized Gains	48
Gross Unrealized Losses	(302)
Fair Value	29,080
Greater Than One Year [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	33,779
Gross Unrealized Gains	0
Gross Unrealized Losses	(73)
Fair Value	$ 33,706

Income Taxes

3 Months Ended

Mar. 31, 2021

Income Tax Disclosure [Abstract]

Income Taxes

10.	Income Taxes

During the three months ended March 31, 2021 and 2020, we recorded income tax expense of $6.5 million and $712, respectively.

Tax expense reflects taxes due to the taxing authorities and the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting and tax purposes, and net operating loss and tax credit carryforwards. The significant components of our total deferred tax liability as of March 31, 2021 and December 31, 2020 relate to the tax effects of the basis difference between the intangible assets acquired in our acquisitions for financial reporting and for tax purposes along with basis differences arising from accelerated tax depreciation of fixed assets.

In 2008, we established a full valuation allowance against our U.S. deferred tax asset. Management believes the full valuation allowance is still appropriate at both March 31, 2021 and December 31, 2020 since the facts and circumstances necessitating the allowance have not changed.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

Stockholders' Equity - Summary of Time-Vested Restricted Stock Award and Restricted Stock Units Activity (Detail) - Restricted Stock Award and Restricted Stock Units [Member] shares in Thousands	3 Months Ended
	Mar. 31, 2021 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Issued and unvested, Beginning Balance	659
Shares, Granted	275
Shares, Vested	(206)
Shares, Forfeited	(5)
Shares, Issued and unvested, Ending Balance	723

Leases (Tables)

3 Months Ended

Mar. 31, 2021

Lessee Disclosure [Abstract]

Summary of Components of Lease Expense

The components of lease expense are as follows:

	Three Months Ended
	2021		2020
Operating Lease Cost	$	420	$	313
Finance Lease Cost
Amortization of right-of use assets		127		163
Interest on lease liabilities		14		20
Total Finance Lease Cost	$	141	$	183

Summary of Supplemental Cash Flow Information Related to Leases

Supplemental cash flow information related to leases is as follows:

	Three Months Ended
	2021		2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	408	$	316
Operating cash flows from financing leases		14		20
Financing cash flows from financing leases		282		175
Non-cash activity:
Right-of-use assets obtained in exchange for operating lease obligations		629		—
Right-of-use assets obtained in exchange for finance lease obligations		—		—

Summary of Supplemental Balance Sheet Information Related to Leases

Supplemental balance sheet information related to leases is as follows:

	March 31, 2021		December 31, 2020
Operating Leases
Right-of-use assets	$	4,871	$	4,461

Current lease liabilities		1,443		1,125
Non-current lease liabilities		3,557		3,591
Total operating lease liabilities	$	5,000	$	4,716


Finance Leases
Right-of-use assets	$	1,184	$	1,312

Current lease liabilities		522		517
Non-current lease liabilities		762		895
Total finance lease liabilities	$	1,284	$	1,412

Summary of Lease Term and Discount Rate

Weighted Average Remaining Lease Term
Weighted-average remaining lease term—operating leases	3.99
Weighted-average remaining lease term—finance leases	2.43

Weighted Average Discount Rate
Weighted-average discount rate—operating leases	4.12	%
Weighted-average discount rate—finance leases	4.39	%

Schedule of Minimum Lease Payments by Period Expected

As of March 31, 2021, minimum lease payments by period are expected to be as follows:


	Finance			Operating
2021 (excluding the three months ended March 31, 2021)	$	424		$	1,236
2022		566			1,616
2023		336			901
2024		25			909
2025		5			518
Thereafter		—			323
Total Minimum Lease Payments		1,356			5,503
Less: imputed interest		(72	)		(503	)
Present Value of Lease Liabilities	$	1,284		$	5,000

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2021

Accounting Policies [Abstract]

Principles of Consolidation and Basis of Presentation

Principles of Consolidation and Basis of Presentation. The accompanying interim unaudited consolidated financial statements include the accounts of OraSure and its wholly-owned subsidiaries, DNAG, Diversigen and Novosanis. All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated. The unaudited financial statements, in the opinion of management, include all adjustments (consisting only of normal and recurring adjustments) necessary for a fair presentation of our financial position and results of operations for these interim periods. These financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020. Results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results of operations expected for the full year.

Summary of Significant Accounting Policies. There have been no changes to the Company's significant accounting policies described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 that have had a material impact on the consolidated financial statements and related notes except as discussed herein.

Investments

Investments. We consider all investments in debt securities to be available-for-sale securities. These securities consist of guaranteed investment certificates and corporate bonds with purchased maturities greater than ninety days. Available-for-sale securities are carried at fair value, based

upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive loss.

We record an allowance for credit loss for our available-for-sale securities when a decline in investment market value is due to credit-related factors. When evaluating an investment for impairment, we review factors such as the severity of the impairment, changes in underlying credit ratings, forecasted recovery, the Company’s intent to sell or the likelihood that it would be required to sell the investment before its anticipated recovery in market value and the probability that the scheduled cash payments will continue to be made. As of March 31, 2021, we determined that the decline in the market value of our available-for-sale investment was not due to credit-related factors and as such no allowance for credit-loss was necessary.

The following is a summary of our available-for-sale securities as of March 31, 2021 and December 31, 2020:

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
March 31, 2021
Guaranteed investment certificates	$	25,470	$	—	$	—		$	25,470
Corporate bonds		37,643		48		(375	)		37,316
Total available-for-sale securities	$	63,113	$	48	$	(375	)	$	62,786
December 31, 2020
Guaranteed investment certificates	$	25,132	$	—	$	—		$	25,132
Corporate bonds		71,533		135		(483	)		71,185
Total available-for-sale securities	$	96,665	$	135	$	(483	)	$	96,317
At March 31, 2021, maturities of our available-for-sale securities were as follows:
Less than one year	$	29,334	$	48	$	(302	)	$	29,080
Greater than one year	$	33,779	$	—	$	(73	)	$	33,706

Fair Value of Financial Instruments

Fair Value of Financial Instruments. As of March 31, 2021 and December 31, 2020, the carrying values of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate their respective fair values based on their short-term nature.

Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

All of our available-for-sale debt securities are measured as Level 2 instruments as of March 31, 2021 and December 31, 2020. Our guaranteed investment certificates are measured as Level 1 instruments as of March 31, 2021 and December 31, 2020.

Included in cash and cash equivalents at March 31, 2021 and December 31, 2020, was $72,979 and $71,489 invested in government money market funds. These funds have investments in government securities and are measured as Level 1 instruments.

We offer a nonqualified deferred compensation plan for certain eligible employees and members of our Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds. The fair value of the plan assets as of March 31, 2021 and December 31, 2020 was $2,396 and $2,565, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in both current assets and noncurrent assets with the same amount included in accrued expenses and other noncurrent liabilities in the accompanying consolidated balance sheets.

Accounts Receivable

Accounts Receivable. Accounts receivable have been reduced by an estimated allowance for amounts that may become uncollectible in the future. This estimated allowance is based primarily on management’s evaluation of specific balances as they become past due, the financial condition of our customers and our historical experience related to write-offs.

Inventories

Inventories. Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis, and include the cost of raw materials, labor and overhead. The majority of our inventories are subject to expiration dating, which can be extended in certain circumstances. We continually evaluate quantities on hand and the carrying value of our inventories to determine the need for reserves for excess and obsolete inventories, based on prior experience as well as estimated forecasts of product sales. We reserve for unidentified scrap or spoilage based on historical write-off rates. We also consider items identified through specific identification procedures in assessing the adequacy of our reserve. When factors indicate that impairment has occurred, either a reserve is established against the inventories’ carrying value or the inventories are completely written off, as in the case of lapsing expiration dates.

Property, Plant and Equipment

Property, Plant and Equipment. Property, plant and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold, retired, or discarded, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statements of operations. Accumulated depreciation of property, plant and equipment as of March 31, 2021 and December 31, 2020 was $55,251 and $53,604, respectively.

Intangible Assets

Intangible Assets. Intangible assets consist of customer relationships, patents and product rights, acquired technology and tradenames. Patents and product rights consist of costs associated with the acquisition of patents, licenses, and product distribution rights. Intangible assets are amortized using the straight-line method over their estimated useful lives of five to fifteen years. Accumulated amortization of intangible assets as of March 31, 2021 and December 31, 2020 was $28,128 and $27,107, respectively. The decrease in intangibles from $17,904 as of December 31, 2020 to $16,945 as of March 31, 2021 is due to $812 in amortization expense and foreign currency translation losses of $147.

Goodwill

Goodwill. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current generally accepted accounting principles (“GAAP”) permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the carrying value of a reporting unit is greater than its fair value, then we would be required to recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value, provided the impairment charge does not exceed the total amount of goodwill allocated to the reporting unit.

The increase in goodwill from $40,351 as of December 31, 2020 to $40,493 as of March 31, 2021 is a result of an adjustment of $124 associated with foreign currency translation and a purchase price adjustment of $18 related to a business acquisition.

Foreign Currency Translation

Foreign Currency Translation. The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity.

Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than a functional currency are included in our consolidated statements of income in the period in which the change occurs. Net foreign exchange gains (losses) resulting from foreign currency transactions that are included in other income in our consolidated statements of income were $(576) and $693 for the three months ended March 31, 2021 and 2020, respectively.

Accumulated Other Comprehensive Income (Loss)

Accumulated Other Comprehensive Income (Loss). We classify items of other comprehensive income (loss) by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our consolidated balance sheets.

We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and we have defined the Euro as the functional currency of our Belgian subsidiary, Novosanis. The results of operations for those subsidiaries are translated into U.S. dollars, which is the reporting currency of the Company. Accumulated other comprehensive loss at March 31, 2021 consists of $7,397 of currency translation adjustments and $327 of net unrealized losses on marketable securities, which represents the fair market value adjustment for our investment portfolio. Accumulated other comprehensive loss at December 31, 2020 consists of $8,749 of currency translation adjustments and $348 of net unrealized losses on marketable securities, which represents the fair market value adjustment for our investments portfolio.

Recent Accounting Pronouncements

Recent Accounting Pronouncements.

In March 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-04, Reference Rate Reform (Topic 848) Facilitation of the Effects of Reference Rate Reform on Financial Reporting. The purpose of this update is to provide optional guidance for a limited time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The amendments provide optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments in this update are elective and are effective upon issuance for all entities. Management is evaluating the impact of this ASU and does not expect this update to have a material impact on the Company's Consolidated Financial Statements.

Revenues by Product

Revenues by product. The following table represents total net revenues by product line:

	Three Months Ended March 31,
	2021		2020
Infectious disease testing	$	11,371	$	14,664
Risk assessment testing		1,962		3,000
Genomics		11,064		8,393
Microbiome		2,088		1,577
COVID-19		27,389		394
Laboratory services		2,497		2,415
Other product and service revenues		208		443
Net product and services revenues		56,579		30,886
Royalty income		1,261		446
Other non-product revenues		742		264
Other revenues		2,003		710
Net revenues	$	58,582	$	31,596

Revenues by Geographic Area

Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer:

	Three Months Ended March 31,
	2021		2020
United States	$	49,100	$	21,616
Europe		4,552		2,805
Other regions		4,930		7,175
	$	58,582	$	31,596

Customer and Vendor Concentrations

Customer and Vendor Concentrations. We had no significant customer concentrations (greater than 10%) in our accounts receivable at March 31, 2021. One of our customers accounted for 11% of our accounts receivable as of December 31, 2020. One customer accounted for 17% of net consolidated revenues for the three months ended March 31, 2021. We had no significant customer concentrations in our net consolidated revenues for the three months ended March 31, 2020.

We currently purchase certain products and critical components of our products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our

products to our customers. Third-party suppliers also manufacture certain products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.

Deferred Revenue

Deferred Revenue. We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of March 31, 2021 and December 31, 2020 includes customer prepayments of $3,000 and $3,216, respectively. Deferred revenue as of March 31, 2021 and December 31, 2020 also includes $1,580 and $1,595, respectively, associated with a long-term contract that has variable pricing based on volume. The average price over the life of the contract was determined and revenue is recognized at that average price.

Accrued Expenses and Other Current Liabilities (Tables)

3 Months Ended

Mar. 31, 2021

Payables And Accruals [Abstract]

Schedule of Accrued Expenses and Other Current Liabilities

	March 31, 2021		December 31, 2020
Payroll and related benefits	$	8,037	$	14,769
Professional fees		1,150		978
Accrued income taxes		2,507		—
Sales tax payable		2,572		2,400
Other		2,737		4,080
	$	17,003	$	22,227

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
NET REVENUES:
Total revenue	$ 58,582	$ 31,596
COST OF PRODUCTS AND SERVICES SOLD	20,256	15,465
Gross profit	38,326	16,131
OPERATING EXPENSES:
Research and development	8,992	5,644
Sales and marketing	9,530	7,369
General and administrative	10,188	10,054
Change in the estimated fair value of acquisition-related contingent consideration	(806)	1,110
Total operating expenses	27,904	24,177
Operating income (loss)	10,422	(8,046)
OTHER INCOME (LOSS)	(119)	1,430
Income (loss) before income taxes	10,303	(6,616)
INCOME TAX EXPENSE	6,529	712
NET INCOME (LOSS)	$ 3,774	$ (7,328)
INCOME (LOSS) PER SHARE:
BASIC	$ 0.05	$ (0.12)
DILUTED	$ 0.05	$ (0.12)
SHARES USED IN COMPUTING INCOME (LOSS) PER SHARE:
BASIC	71,878	61,927
DILUTED	72,766	61,927
Products and Services [Member]
NET REVENUES:
Total revenue	$ 56,579	$ 30,886
Other Revenues [Member]
NET REVENUES:
Total revenue	$ 2,003	$ 710

The Company

3 Months Ended

Mar. 31, 2021

Organization Consolidation And Presentation Of Financial Statements [Abstract]

The Company

1.	The Company

The overall goal of OraSure Technologies, Inc. (“OraSure” or “the Company”) is to empower the global community to improve health and wellness by providing access to accurate essential information. Our business consists of two segments: our “Diagnostics” segment, and our “Molecular Solutions” segment. Our Diagnostics business primarily consists of the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using our proprietary technologies, as well as other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Our Molecular Solutions business consists of the manufacture and sale of kits that are used to collect, stabilize, transport and store biological samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, infectious disease diagnostics, pharmacogenomics, personalized medicine, microbiome and animal genetics markets. Our collection kits are also used for the collection of first-void urine for liquid biopsy in the prostate and bladder cancer markets and in the sexually transmitted infection screening market. In addition, our Molecular Solutions business provides microbiome laboratory and bioinformatics services.

The Diagnostics business includes tests for diseases including HIV and Hepatitis C that are performed on a rapid basis at the point of care and tests that are processed in a laboratory. These products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. Our HIV product is also sold in a consumer-friendly format in the over-the-counter (“OTC”) market in the U.S. and as a self-test to individuals in a number of other countries. Our Diagnostics business includes the operations of UrSure, Inc. (“UrSure”), which was acquired and merged into OraSure in 2020. This part of the Diagnostics business develops and commercializes products that measure adherence to HIV medications including pre-exposure prophylaxis or PrEP, the daily medication to prevent HIV, and anti-retroviral medications to suppress HIV. These products include laboratory-based tests that can measure levels of the medications in a patient’s urine or blood, as well as point-of-care products currently in development. In 2020, we developed a rapid antigen self-test for COVID-19 and a COVID-19 antibody enzyme-linked immunosorbent assay (“ELISA”) for use in laboratory settings. We are seeking Emergency Use Authorization (“EUA”) from the U.S. Food and Drug Administration “FDA”) for these products.

Our Molecular Solutions business is operated by our subsidiaries, DNA Genotek Inc. (“DNAG”), Diversigen, Inc. (“Diversigen”), and Novosanis NV (“Novosanis”). In this business, we manufacture and sell kits that are used to collect, stabilize, transport and store a biological sample of genetic material for molecular testing. Our products are used for academic research and commercial applications, including ancestry, disease risk management, lifestyle and animal testing. In 2020, three of our collection devices were used in connection with COVID-19 molecular testing. We also sell research-use-only collection products into the microbiome market. We offer our customers a suite of genomics and microbiome services that range from package customization and study design optimization to extraction, analysis and reporting services. The microbiome laboratory and bioinformatics services are provided by Diversigen, which includes the operations of CoreBiome, Inc. (“CoreBiome”), a subsidiary we acquired in early 2019. CoreBiome and Diversigen were merged together in 2020. Novosanis manufactures and sells the Colli-Pee® collection device for the volumetric collection of first-void urine for use in research, screening and diagnostics in the liquid biopsy and sexually transmitted infection markets. Our Molecular Solutions business serves customers in many countries worldwide, including many leading research universities and hospitals.

Stockholders' Equity - Summary of Reconciliation of Changes in Stockholders' Equity (Detail) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Beginning Balance	$ 398,571	$ 307,145
Common stock issued upon exercise of options	$ 92	30
Common stock issued upon exercise of options, Shares	11
Purchase and retirement of common shares	$ (1,730)	(1,408)
Stock-based compensation	1,464	1,376
Net income (loss)	3,774	(7,328)
Currency translation adjustments	1,352	(9,221)
Unrealized gain (loss) on marketable securities	21	(442)
Ending Balance	$ 403,544	$ 290,152
Common Stock [Member]
Beginning Balance, Shares	71,738	61,731
Common stock issued upon exercise of options, Shares	11	6
Vesting of restricted stock and performance stock units, Shares	318	486
Purchase and retirement of common shares, Shares	(111)	(197)
Ending Balance, Shares	71,956	62,026
Additional Paid-in Capital [Member]
Beginning Balance	$ 505,123	$ 401,814
Common stock issued upon exercise of options	92	30
Purchase and retirement of common shares	(1,730)	(1,408)
Stock-based compensation	1,464	1,376
Ending Balance	504,949	401,812
Accumulated Other Comprehensive Loss [Member]
Beginning Balance	(9,097)	(12,136)
Currency translation adjustments	1,352	(9,221)
Unrealized gain (loss) on marketable securities	21	(442)
Ending Balance	(7,724)	(21,799)
Accumulated Deficit [Member]
Beginning Balance	(97,455)	(82,533)
Net income (loss)	3,774	(7,328)
Ending Balance	$ (93,681)	$ (89,861)

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Accrued Liabilities Current [Abstract]
Payroll and related benefits	$ 8,037	$ 14,769
Professional fees	1,150	978
Accrued income taxes	2,507
Sales tax payable	2,572	2,400
Other	2,737	4,080
Accrued expenses and other current liabilities, Total	$ 17,003	$ 22,227

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Income tax expense (benefit)	$ 6,529	$ 712

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

Revenues

3 Months Ended

Mar. 31, 2021

Revenue From Contract With Customer [Abstract]

Revenues

Revenues by product. The following table represents total net revenues by product line:

	Three Months Ended March 31,
	2021		2020
Infectious disease testing	$	11,371	$	14,664
Risk assessment testing		1,962		3,000
Genomics		11,064		8,393
Microbiome		2,088		1,577
COVID-19		27,389		394
Laboratory services		2,497		2,415
Other product and service revenues		208		443
Net product and services revenues		56,579		30,886
Royalty income		1,261		446
Other non-product revenues		742		264
Other revenues		2,003		710
Net revenues	$	58,582	$	31,596

Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer:

	Three Months Ended March 31,
	2021		2020
United States	$	49,100	$	21,616
Europe		4,552		2,805
Other regions		4,930		7,175
	$	58,582	$	31,596

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

+ Details

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2021

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2.	Summary of Significant Accounting Policies

upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive loss.

The following is a summary of our available-for-sale securities as of March 31, 2021 and December 31, 2020:

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
March 31, 2021
Guaranteed investment certificates	$	25,470	$	—	$	—		$	25,470
Corporate bonds		37,643		48		(375	)		37,316
Total available-for-sale securities	$	63,113	$	48	$	(375	)	$	62,786
December 31, 2020
Guaranteed investment certificates	$	25,132	$	—	$	—		$	25,132
Corporate bonds		71,533		135		(483	)		71,185
Total available-for-sale securities	$	96,665	$	135	$	(483	)	$	96,317
At March 31, 2021, maturities of our available-for-sale securities were as follows:
Less than one year	$	29,334	$	48	$	(302	)	$	29,080
Greater than one year	$	33,779	$	—	$	(73	)	$	33,706

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

Recent Accounting Pronouncements.

Stockholders' Equity

3 Months Ended

Mar. 31, 2021

Equity [Abstract]

Stockholders' Equity

9.Stockholders’ Equity

Reconciliation of the changes in stockholders' equity for the three months ended March 31, 2021 and 2020
	Common Stock					Additional Paid-in			Accumulated Other Comprehensive			Accumulated
	Shares			Amount		Capital			Loss			Deficit			Total
Balance at December 31, 2020		71,738		$	—	$	505,123		$	(9,097	)	$	(97,455	)	$	398,571
Common stock issued upon exercise of options		11			—		92			—			—			92
Vesting of restricted stock and performance stock units		318			—					—			—			—
Purchase and retirement of common shares		(111	)		—		(1,730	)		—			—			(1,730	)
Stock-based compensation		—			—		1,464			—			—			1,464
Net income		—			—		—			—			3,774			3,774
Currency translation adjustments		—			—		—			1,352			—			1,352
Unrealized gain on marketable securities		—			—		—			21			—			21
Balance at March 31, 2021		71,956		$	—	$	504,949		$	(7,724	)	$	(93,681	)	$	403,544


	Common Stock					Additional Paid-in			Accumulated Other Comprehensive			Accumulated
	Shares			Amount		Capital			Loss			Deficit			Total
Balance at December 31, 2019		61,731		$	—	$	401,814		$	(12,136	)	$	(82,533	)	$	307,145
Common stock issued upon exercise of options		6			—		30			—			—			30
Vesting of restricted stock and performance stock units		486			—		—			—			—			—
Purchase and retirement of common shares		(197	)		—		(1,408	)		—			—			(1,408	)
Stock-based compensation		—			—		1,376			—			—			1,376
Net loss		—			—		—			—			(7,328	)		(7,328	)
Currency translation adjustments		—			—		—			(9,221	)		—			(9,221	)
Unrealized loss on marketable securities		—			—		—			(442	)		—			(442	)
Balance at March 31, 2020		62,026		$	—	$	401,812		$	(21,799	)	$	(89,861	)	$	290,152

Stock-Based Awards

We grant stock-based awards under the OraSure Technologies, Inc. Stock Award Plan, as amended (the “Stock Plan”). The Stock Plan permits stock-based awards to employees, outside directors and consultants or other third-party advisors. Awards which may be granted under the Stock Plan include qualified incentive stock options, nonqualified stock options, stock appreciation rights, restricted awards, performance awards and other stock-based awards. We account for stock-based compensation to employees and directors using the fair value method. We recognize compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. We recognize compensation expense related to performance-based restricted stock units based on assumptions as to what percentage of each performance target will be achieved. We evaluate these target assumptions on a quarterly basis and adjust compensation expense related to these awards, as appropriate. To satisfy the exercise of options, issuance of restricted stock, or redemption of performance-based restricted stock units, we issue new shares rather than shares purchased on the open market.

Total compensation cost related to stock options for the three months ended March 31, 2021 and 2020 was $250 and $253 respectively. Net cash proceeds from the exercise of stock options were $92 and $30 for the three months ended March 31, 2021 and 2020, respectively. As a result of our net operating loss carryforward position, no actual income tax benefit was realized from stock option exercises during these periods.

The following table summarizes the stock option activity for the three months ended March 31, 2021:

	Options
Outstanding on January 1, 2021		1,232
Granted		252
Exercised		(11	)
Forfeited		(23	)
Outstanding on March 31, 2021		1,450

Compensation cost of $1,036 and $1,079 related to restricted shares was recognized during the three months ended March 31, 2021 and 2020, respectively.

The following table summarizes time-vested restricted stock award and restricted stock unit activity for the three months ended March 31, 2021:

	Units
Issued and unvested, January 1, 2021		659
Granted		275
Vested		(206	)
Forfeited		(5	)
Issued and unvested, March 31, 2021		723

We grant performance-based restricted stock units (“PSUs”) to certain executives. Vesting of these PSUs is dependent upon achievement of performance-based metrics during a one-year or three-year period from the date of grant. Assuming achievement of each performance-based metric, the executive must also generally remain employed for three years from the grant date. Performance during the one-year period is based on a one-year income before income taxes target. If the one-year target is achieved, the PSUs will then vest three years from grant date.

Performance during the three-year period will be based on achievement of a three-year compound annual growth rate for consolidated product revenues. If the three-year target is achieved, the corresponding PSUs will then vest three years from grant date. PSUs are converted into shares of our common stock once vested.

Compensation cost of $178 and $44 related to PSUs was recognized during the three months ended March 31, 2021 and 2020, respectively.

The following table summarizes the PSU activity for the three months ended March 31, 2021:

	Units
Issued and unvested, January 1, 2021		651
Granted		186
Performance adjustment		37
Vested		(112	)
Forfeited		(49	)
Issued and unvested, March 31, 2021		713

Stock Repurchase Program

On August 5, 2008, our Board of Directors approved a share repurchase program pursuant to which we are permitted to acquire up to $25,000 of our outstanding common shares. No shares were purchased and retired during the three months ended March 31, 2021 and 2020.

Business Combinations

3 Months Ended

Mar. 31, 2021

Business Combinations [Abstract]

Business Combinations

3. Business Combinations

UrSure

On July 22, 2020, the Company acquired all of the outstanding capital stock of UrSure, Inc. (“UrSure”), pursuant to the terms of a merger agreement. The initial aggregate purchase price of this transaction was $3,000, adjusted for certain transaction costs, indebtedness, and holdback amounts, and was funded with cash on hand. A portion of the purchase price was deposited into an escrow account for a limited period after closing, pursuant to indemnification obligations under the merger agreement.

During the three months ended March 31, 2020, we incurred acquisition related costs of $393 including accounting, legal, and other professional fees, all of which were expensed and reported as a component of general and administrative expense in the consolidated statement of operations. No such costs were incurred for the three months ended March 31, 2021.

Pursuant to our merger agreement, we may pay up to an additional $28,000 of contingent consideration over the next four years based on the achievement of certain performance criteria as defined under the agreements, including generating certain revenue dollars, and the achievement of certain clinical milestones associated with the development of certain new technology. The Company, with the assistance of an independent valuation specialist, determined the estimated acquisition-date fair value of the acquisition-related contingent consideration of $3,440. The fair value was determined using a probability-weighted model based on our assessment of the likelihood that the benchmarks will be achieved. The probability-weighted payments were then discounted using a discount rate based on an internal rate of return analysis using the probability-weighted cash flows. The fair value measurement was based on significant inputs, including the likelihood of the achievement of clinical milestones and revenue forecasts, not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy.

The following table represents the change in contingent consideration:

Balance as of December 31, 2020	$	2,451
Payments made during the period		(406	)
Change in fair value during the period		(806	)
Balance as of March 31, 2021	$	1,239

Revenues from UrSure primarily consist of grant money received to fund the development of certain new technology. Effective as of July 22, 2020, the financial results of UrSure are included in our Diagnostics segment.

Revenues - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Revenue from contract with customer [Line Items]
Deferred revenue	$ 4,580	$ 4,811
Long-term Contract [Member]
Revenue from contract with customer [Line Items]
Deferred revenue	1,580	1,595
Up Front Payment Arrangement [Member]
Revenue from contract with customer [Line Items]
Deferred revenue	$ 3,000	$ 3,216
Customer [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member]
Revenue from contract with customer [Line Items]
Percentage of concentration risk		11.00%
Customer [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member] \| Maximum [Member]
Revenue from contract with customer [Line Items]
Percentage of concentration risk	10.00%
Customer [Member] \| Net Consolidated Revenue [Member] \| Customer Concentration Risk [Member]
Revenue from contract with customer [Line Items]
Percentage of concentration risk	17.00%

Stockholders' Equity - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Aug. 05, 2008
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	$ 1,464,000	$ 1,376,000
Proceeds from exercise of stock options	92,000	30,000
Income tax benefit realized from stock option exercises during period	0	0
Amount share repurchase program of common shares			$ 25,000,000
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	250,000	253,000
Proceeds from exercise of stock options	92,000	30,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	$ 1,036,000	1,079,000
Performance Based Restricted Stock [Member] \| Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Performance Based Restricted Stock [Member] \| Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Performance Based Restricted Stock Unit [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	$ 178,000	$ 44,000
Share Repurchase Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares purchased and retired	0	0

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
OPERATING ACTIVITIES:
Net income (loss)	$ 3,774	$ (7,328)
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:
Stock-based compensation	1,464	1,376
Depreciation and amortization	2,489	2,165
Other non-cash amortization	138	32
Provision for doubtful accounts	598	26
Unrealized foreign currency gain	(100)	(224)
Interest expense on finance leases	14	20
Deferred income taxes	(94)	(71)
Change in the estimated fair value of acquisition-related contingent consideration	(806)	1,110
Payment of acquisition-related contingent consideration	(142)	(496)
Changes in assets and liabilities
Accounts receivable	2,188	8,623
Inventories	(8,382)	248
Prepaid expenses and other assets	(766)	1,035
Accounts payable	(253)	(3,094)
Deferred revenue	(262)	780
Accrued expenses and other liabilities	(4,253)	(1,703)
Net cash (used in) provided by operating activities	(4,393)	2,499
INVESTING ACTIVITIES:
Purchases of investments		(36,945)
Proceeds from maturities and redemptions of investments	33,745	55,811
Purchases of property and equipment	(11,061)	(2,595)
Proceeds from escrow associated with business acquisitions		126
Purchase price adjustment related to business acquisition	(19)
Purchase of patent and product rights		(2,250)
Net cash provided by investing activities	22,665	14,147
FINANCING ACTIVITIES:
Cash payments for lease liabilities	(282)	(175)
Payment of acquisition-related contingent consideration	(264)	(3,004)
Proceeds from exercise of stock options	92	30
Repurchase of common stock	(1,730)	(1,408)
Net cash used in financing activities	(2,184)	(4,557)
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH	786	(4,439)
NET INCREASE IN CASH AND CASH EQUIVALENTS	16,874	7,650
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	160,802	75,715
CASH AND CASH EQUIVALENTS, END OF PERIOD	177,676	83,365
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for income taxes	3,671	(85)
Non-cash investing and financing activities
Accrued property and equipment purchases	4,267	1,129
Unrealized gain (loss) on marketable securities	$ 21	$ (442)

Business Segment Information (Tables)

3 Months Ended

Mar. 31, 2021

Segment Reporting [Abstract]

Summary of Operating Segment and Asset Information

The following table summarizes operating segment information for the three months ended March 31, 2021 and 2020, and asset information as of March 31, 2021 and December 31, 2020:

	Three Months Ended March 31,
	2021			2020
Net revenues:
Diagnostics	$	14,546		$	17,792
Molecular Solutions		44,036			13,804
Total	$	58,582		$	31,596
Operating income (loss):
Diagnostics	$	(12,193	)	$	(7,641	)
Molecular Solutions		22,615			(405	)
Total	$	10,422		$	(8,046	)
Depreciation and amortization:
Diagnostics	$	890		$	861
Molecular Solutions		1,599			1,336
Total	$	2,489		$	2,197
Capital expenditures:
Diagnostics	$	7,637		$	818
Molecular Solutions		3,424			1,777
Total	$	11,061		$	2,595

	March 31, 2021		December 31, 2020
Total assets:
Diagnostics	$	221,858	$	242,613
Molecular Solutions		234,638		211,859
Total	$	456,496	$	454,472

Revenues (Tables)

3 Months Ended

Mar. 31, 2021

Revenue From Contract With Customer [Abstract]

Disaggregation of Revenue by Product and Geographic Area

Revenues by product. The following table represents total net revenues by product line:

	Three Months Ended March 31,
	2021		2020
Infectious disease testing	$	11,371	$	14,664
Risk assessment testing		1,962		3,000
Genomics		11,064		8,393
Microbiome		2,088		1,577
COVID-19		27,389		394
Laboratory services		2,497		2,415
Other product and service revenues		208		443
Net product and services revenues		56,579		30,886
Royalty income		1,261		446
Other non-product revenues		742		264
Other revenues		2,003		710
Net revenues	$	58,582	$	31,596

Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer:

	Three Months Ended March 31,
	2021		2020
United States	$	49,100	$	21,616
Europe		4,552		2,805
Other regions		4,930		7,175
	$	58,582	$	31,596

Leases - Summary of Supplemental Cash Flow Information Related to Leases (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 408	$ 316
Operating cash flows from financing leases	14	20
Financing cash flows from financing leases	282	$ 175
Non-cash activity:
Right-of-use assets obtained in exchange for operating lease obligations	$ 629

Leases - Summary of Supplemental Balance Sheet Information Related to Leases (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Operating Leases
Right-of-use assets	$ 4,871	$ 4,461
Current lease liabilities	1,443	1,125
Non-current lease liabilities	3,557	3,591
Total operating lease liabilities	5,000	4,716
Finance Leases
Right-of-use assets	1,184	1,312
Current lease liabilities	522	517
Non-current lease liabilities	762	895
Total finance lease liabilities	$ 1,284	$ 1,412

Business Segment Information

3 Months Ended

Mar. 31, 2021

Segment Reporting [Abstract]

Business Segment Information

12.	Business Segment Information

Our business consists of two segments: our “Diagnostics” business, which primarily consists of the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using our proprietary technologies, other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Our Diagnostics segment includes the financial results of UrSure. Our “Molecular Solutions” business consists of the development, manufacture, marketing and sale of specimen collection kits that are used to collect, stabilize, transport and store samples of genetic material for molecular testing. Our collection kits are also used for the collection of first-void urine for liquid biopsy in the prostate and bladder cancer markets; and in the sexually transmitted infection screening market. In addition, our Molecular Solutions business provides microbiome laboratory services that accelerate research and discovery for customers in the pharmaceutical, agricultural, and academic research markets. Financial results of Diversigen and Novosanis are included in our Molecular Solutions segment.

We organized our operating segments according to the nature of the products included in those segments. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 2). We evaluate performance of our operating segments based on revenue and operating income. We do not allocate interest income, interest expense, other income, other expenses or income taxes to our operating segments. Reportable segments have no inter-segment revenues and inter-segment expenses have been eliminated.

The following table summarizes operating segment information for the three months ended March 31, 2021 and 2020, and asset information as of March 31, 2021 and December 31, 2020:

	Three Months Ended March 31,
	2021			2020
Net revenues:
Diagnostics	$	14,546		$	17,792
Molecular Solutions		44,036			13,804
Total	$	58,582		$	31,596
Operating income (loss):
Diagnostics	$	(12,193	)	$	(7,641	)
Molecular Solutions		22,615			(405	)
Total	$	10,422		$	(8,046	)
Depreciation and amortization:
Diagnostics	$	890		$	861
Molecular Solutions		1,599			1,336
Total	$	2,489		$	2,197
Capital expenditures:
Diagnostics	$	7,637		$	818
Molecular Solutions		3,424			1,777
Total	$	11,061		$	2,595

	March 31, 2021		December 31, 2020
Total assets:
Diagnostics	$	221,858	$	242,613
Molecular Solutions		234,638		211,859
Total	$	456,496	$	454,472

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

Business Combinations - Additional Information (Detail) - USD ($) $ in Thousands		3 Months Ended
	Jul. 22, 2020	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Business Acquisition [Line Items]
Business acquisition contingent consideration, non-current		$ 874		$ 2,049
UrSure Inc [Member]
Business Acquisition [Line Items]
Purchase price	$ 3,000
Acquisition-related costs		$ 0	$ 393
Business acquisition contingent consideration, non-current	$ 28,000
Business combination contingent consideration expected payment period	4 years
Estimated fair value of contingent consideration	$ 3,440

Earnings (Loss) Per Share - Computations of Basic and Diluted Earnings (Loss) Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Earnings Per Share [Abstract]
NET INCOME (LOSS)	$ 3,774	$ (7,328)
SHARES USED IN COMPUTING INCOME (LOSS) PER SHARE:
BASIC	71,878	61,927
Dilutive effect of stock options, restricted stock, and performance stock units	888
Diluted	72,766	61,927
BASIC	$ 0.05	$ (0.12)
DILUTED	$ 0.05	$ (0.12)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details